Thrombin generation testing for monitoring hemophilia treatment: A clinical perspective

Seminars in Thrombosis and Hemostasis

Volumn 36, Issue 7, 2010, Pages 780-790

  Salvagno, Gian Luca ^a   Berntorp, Erik ^b  

^a UNIVERSITY HOSPITAL OF VERONA   (Italy)

^b LUND UNIVERSITY   (Sweden)

Author keywords

coagulation; hemophilia; Thrombin generation assay; von Willebrand disease

Indexed keywords

BLOOD CLOTTING FACTOR 10A; FIBRIN; FIBRINOGEN; THROMBIN;

BLEEDING; BLOOD CLOTTING; FIBRIN CLOT; HEMOPHILIA; HEMOSTASIS; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTHROMBIN TIME; REVIEW; THROMBIN TIME; THROMBOSIS; VON WILLEBRAND DISEASE;

HEMOPHILIA A; HEMOSTATICS; HUMANS; THROMBIN;

EID: 78049279865     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0030-1265295     Document Type: Review

References (86)

1. MacFarlane R G., Biggs R. A thrombin generation test; the application in haemophilia and thrombocytopenia. J Clin Pathol 1953 6 (1) 3-8
2. Pitney W R., Dacie J V. A simple method of studying the generation of thrombin in recalcified plasma; application in the investigation of haemophilia. J Clin Pathol 1953 6 (1) 9-14
3. Hemker H C., Béguin S. Thrombin generation in plasma: its assessment via the endogenous thrombin potential. Thromb Haemost 1995 74 (1) 134-138
4. Hemker H C., Giesen P, AlDieri R et al. The calibrated automated thrombogram (CAT): a universal routine test for hyper- and hypocoagulability. Pathophysiol Haemost Thromb 2002 32 (5-6) 249-253
5. Shima M, Matsumoto T, Ogiwara K. New assays for monitoring haemophilia treatment. Haemophilia 2008 14 (Suppl 3) 83-92
6. Salvagno G L., Astermark J, Lippi G et al. Thrombin generation assay: a useful routine check-up tool in the management of patients with haemophilia? Haemophilia 2009 15 (1) 290-296
7. Beltrán-Miranda C P., Khan A, Jaloma-Cruz A R., Laffan M A. Thrombin generation and phenotypic correlation in haemophilia A. Haemophilia 2005 11 (4) 326-334
8. Jayandharan G R., Srivastava A. The phenotypic heterogeneity of severe hemophilia. Semin Thromb Hemost 2008 34 (1) 128-141
9. Váradi K, Negrier C, Berntorp E et al. Monitoring the bioavailability of FEIBA with a thrombin generation assay. J Thromb Haemost 2003 1 (11) 2374-2380
10. Turecek P L., Váradi K, Keil B et al. Factor VIII inhibitor-bypassing agents act by inducing thrombin generation and can be monitored by a thrombin generation assay. Pathophysiol Haemost Thromb 2003 33 (1) 16-22
11. Dargaud Y, Lambert T, Trossaert M. New advances in the therapeutic and laboratory management of patients with haemophilia and inhibitors. Haemophilia 2008 14 (Suppl 4) 20-27
12. Terraube V, O'Donnell J S., Jenkins P V. Factor VIII and von Willebrand factor interaction: biological, clinical and therapeutic importance. Haemophilia 2010 16 (1) 3-13
13. Hollestelle M J., Thinnes T, Crain K et al. Tissue distribution of factor VIII gene expression in vivoa closer look. Thromb Haemost 2001 86 (3) 855-861
14. Collins P W., Blanchette V S., Fischer K et al. rAHF-PFM Study Group. Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe haemophilia A. J Thromb Haemost 2009 7 (3) 413-420
15. Biggs R A., Douglas A S., MacFarlane R G., Dacie J V., Pitney W R., Merskey. Christmas disease: a condition previously mistaken for haemophilia. BMJ 1952 2 (4799) 1378-1382
16. van den Berg H M., De Groot P H., Fischer K. Phenotypic heterogeneity in severe hemophilia. J Thromb Haemost 2007 5 (Suppl 1) 151-156
17. Vicente V. Factor VIII half-life and intensity of treatment in hemophilic patients. Haematologica 2005 90 (4) 437
18. Franchini M, Montagnana M, Targher G et al. Interpatient phenotypic inconsistency in severe congenital hemophilia: a systematic review of the role of inherited thrombophilia. Semin Thromb Hemost 2009 35 (3) 307-312
19. Oldenburg J, Dolan G, Lemm G. Haemophilia care then, now and in the future. Haemophilia 2009 15 (Suppl 1) 2-7
20. Dargaud Y, Negrier C. Thrombin generation testing in haemophilia comprehensive care centres. Haemophilia 2010 16 (2) 223-230
21. Schwaab R, Oldenburg J, Kemball-Cook G et al. Assay discrepancy in mild haemophilia A due to a factor VIII missense mutation (Asn694Ile) in a large Danish family. Br J Haematol 2000 109 (3) 523-528
22. van Dijk K, van der Bom J G., Lenting P J. et al. Factor VIII half-life and clinical phenotype of severe hemophilia A. Haematologica 2005 90 (4) 494-498
23. Molho P, Rolland N, Lebrun T et al, The French Study Group. Epidemiological survey of the orthopaedic status of severe haemophilia A and B patients in France. The French Study Group.secretariat.haemophiles@cch.ap-hop- paris.fr. Haemophilia 2000 6 (1) 23-32
24. Plug I, van der Bom J G., Peters M et al. Thirty years of hemophilia treatment in the Netherlands, 19722001. Blood 2004 104 (12) 3494-3500
25. Gilmore R, Harmon S, Gannon C, Byrne M, O'Donnell J S., Jenkins P V. Thrombin generation in haemophilia A patients with mutations causing factor VIII assay discrepancy. Haemophilia 2010 16 (4) 671-674
26. Berntorp E, Salvagno G L. Standardization and clinical utility of thrombin-generation assays. Semin Thromb Hemost 2008 34 (7) 670-682
27. Bolton-Maggs P H., Pasi K J. Haemophilias A and B. Lancet 2003 361 (9371) 1801-1809
28. Aledort L M., Haschmeyer R H., Pettersson H, The Orthopaedic Outcome Study Group. A longitudinal study of orthopaedic outcomes for severe factor-VIII-deficient haemophiliacs. J Intern Med 1994 236 (4) 391-399
29. Ljung R, Petrini P, Nilsson I M. Diagnostic symptoms of severe and moderate haemophilia A and B. A survey of 140 cases. Acta Paediatr Scand 1990 79 (2) 196-200
30. Nilsson I M., Berntorp E, Löfqvist T, Pettersson H. Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B. J Intern Med 1992 232 (1) 25-32
31. Nichols W C., Amano K, Cacheris P M. et al. Moderation of hemophilia A phenotype by the factor V R506Q mutation. Blood 1996 88 (4) 1183-1187
32. Brummel-Ziedins K, Vossen C Y., Rosendaal F R., Umezaki K, Mann K G. The plasma hemostatic proteome: thrombin generation in healthy individuals. J Thromb Haemost 2005 3 (7) 1472-1481
33. Nadeau J H. Modifier genes and protective alleles in humans and mice. Curr Opin Genet Dev 2003 13 (3) 290-295
34. Ginsburg D. Identifying novel genetic determinants of haemostatic balance. J Thromb Haemost 2005 3 (8) 1561-1568
35. Trossaërt M, Regnault V, Sigaud M, Boisseau P, Fressinaud E, Lecompte T. Mild hemophilia A with factor VIII assay discrepancy: using thrombin generation assay to assess the bleeding phenotype. J Thromb Haemost 2008 6 (3) 486-493
36. Santagostino E, Mancuso M E., Tripodi A et al. Severe hemophilia with mild bleeding phenotype: molecular characterization and global coagulation profile. J Thromb Haemost 2010 8 (4) 737-743
37. Colvin B T., Astermark J, Fischer K et al, Inter Disciplinary Working Group. European principles of haemophilia care. Haemophilia 2008 14 (2) 361-374
38. Shima M, Matsumoto T, Ogiwara K. New assays for monitoring haemophilia treatment. Haemophilia 2008 14 (Suppl 3) 83-92
39. van Veen J J., Gatt A, Makris M. Thrombin generation testing in routine clinical practice: are we there yet? Br J Haematol 2008 142 (6) 889-903
40. Dargaud Y, Béguin S, Lienhart A et al. Evaluation of thrombin generating capacity in plasma from patients with haemophilia A and B. Thromb Haemost 2005 93 (3) 475-480
41. Berntorp E, Björkman S. The pharmacokinetics of clotting factor therapy. Haemophilia 2003 9 (4) 353-359
42. Berntorp E. Factor VIII concentrates In: Forbes CD, Aledort L Haemophilia. London, United Kingdom Chapman & Hall 1997 181-192
43. Barrowcliffe T W. Factor VIII and factor IX Sub-Committee. Recommendations for the assay of high-purity factor VIII concentrates. Thromb Haemost 1993 70 (5) 876-877
44. White GC 11, Shapiro A D., Kurczynski E M., Kim H C., Bergman G E., The Mononine Study Group. Variability of in vivo recovery of factor IX after infusion of monoclonal antibody purified factor IX concentrates in patients with haemophilia B. Thromb Haemost 1995 73 (5) 779-784
45. Dunn A L., Abshire T C. Current issues in prophylactic therapy for persons with hemophilia. Acta Haematol 2006 115 (34) 162-171
46. Bolton-Maggs P H. Optimal haemophilia care versus the reality. Br J Haematol 2006 132 (6) 671-682
47. Bassus S, Wegert W, Krause M et al. Platelet-dependent coagulation assays for factor VIII efficacy measurement after substitution therapy in patients with haemophilia A. Platelets 2006 17 (6) 378-384
48. Wight J, Paisley S. The epidemiology of inhibitors in haemophilia A: a systematic review. Haemophilia 2003 9 (4) 418-435
49. Hall M. Haemophilia complicated by an acquired circulating anticoagulant: a report of three cases. Br J Haematol 1961 7 340-348
50. Berntorp E. VWF/FVIII complex and the management of patient with inhibitors: from laboratory to clinical practice. Haemophilia 2007 13 (Suppl 5) 69-72
51. White G C. II, Rosendaal F, Aledort L M., Lusher J M., Rothschild C, Ingerslev J, Factor VIII and Factor IX Subcommittee. Definitions in hemophilia. Recommendation of the Scientific Subcommittee on Factor VIII and Factor IX of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost 2001 85 (3) 560
52. Berntorp E, Shapiro A, Astermark J et al. Inhibitor treatment in haemophilias A and B: summary statement for the 2006 international consensus conference. Haemophilia 2006 12 (Suppl 6) 1-7
53. Astermark J, Oldenburg J, Escobar M, White G C. II, Berntorp E, Malmö International Brother StudyGroup. The Malmö International Brother Study (MIBS). Genetic defects and inhibitor development in siblings with severe hemophilia A. Haematologica 2005 90 (7) 924-931
54. Mannhalter C. The Malmö International Brother Study (MIBS). Genetic defects and inhibitor development in siblings with severe hemophilia A. Haematologica 2005 90 (7) 869A
55. Luu H, Ewenstein B. FEIBA safety profile in multiple modes of clinical and home-therapy application. Haemophilia 2004 10 (Suppl 2) 10-16
56. Berntorp E. Differential response to bypassing agents complicates treatment in patients with haemophilia and inhibitors. Haemophilia 2009 15 (1) 3-10
57. Turecek P L., Váradi K, Keil B et al. Factor VIII inhibitor-bypassing agents act by inducing thrombin generation assay. Pathophysiol Haemost Thromb 2003 33 (1) 16-22
58. Váradi K, Negrier C, Berntorp E et al. Monitoring the bioavailability of FEIBA with a thrombin generation assay. J Thromb Haemost 2003 1 (11) 2374-2380
59. Livnat T, Martinowitz U, Zivelin A, Seligsohn U. Effects of factor VIII inhibitor bypassing activity (FEIBA), recombinant factor VIIa or both on thrombin generation in normal and haemophilia A plasma. Haemophilia 2008 14 (4) 782-786
60. Dargaud Y, Lienhart A, Meunier S et al. Major surgery in a severe haemophilia A patient with high titre inhibitor: use of the thrombin generation test in the therapeutic decision. Haemophilia 2005 11 (5) 552-558
61. Klintman J, Berntorp E, Astermark J, ON BEHALF OF THE MIBS STUDY GROUP . Thrombin generation in vitro in the presence of by-passing agents in siblings with severe haemophilia A. Haemophilia 2009 October 30 (Epub ahead of print)
62. Matsumoto T, Nogami K, Ogiwara K, Shima M. A modified thrombin generation test for investigating very low levels of factor VIII activity in hemophilia A. Int J Hematol 2009 90 (5) 576-582
63. Aljamali M N., Kjalke M, Hedner U, Ezban M, Tranholm M. Thrombin generation and platelet activation induced by rFVIIa (NovoSeven) and NN1731 in a reconstituted cell-based model mimicking haemophilia conditions. Haemophilia 2009 15 (6) 1318-1326
64. Brummel-Ziedins K E., Whelihan M F., Gissel M, Mann K G., Rivard G E. Thrombin generation and bleeding in haemophilia A. Haemophilia 2009 15 (5) 1118-1125
65. Eichinger S, Lubsczyk B, Kollars M et al. Thrombin generation in haemophilia A patients with factor VIII inhibitors after infusion of recombinant factor VIIa. Eur J Clin Invest 2009 39 (8) 707-713
66. Martinowitz U, Livnat T, Zivelin A, Kenet G. Concomitant infusion of low doses of rFVIIa and FEIBA in haemophilia patients with inhibitors. Haemophilia 2009 15 (4) 904-910
67. Rosenthal R L., Dreskin O H., Rosenthal N. Plasma thromboplastin antecedent (PTA) deficiency; clinical, coagulation, therapeutic and hereditary aspects of a new hemophilia-like disease. Blood 1955 10 (2) 120-131
68. Bolton-Maggs P H., Young Wan-Yin B, McCraw A H., Slack J, Kernoff P B. Inheritance and bleeding in factor XI deficiency. Br J Haematol 1988 69 (4) 521-528
69. Bolton-Maggs P H. Factor XI deficiencyresolving the enigma? Hematology Am Soc Hematol Educ Program 2009 97-105
70. Seligsohn U. Factor XI deficiency in humans. J Thromb Haemost 2009 7 (Suppl 1) 84-87
71. Furie B, Furie B C. Molecular basis of blood coagulation In: Hoffman H, Benze EJ, Shattil SJ, et al Hematology, Basic Principles and Practice. 5th ed. Philadelphia, PA Churchill Livingstone-Elsevier 2009 1819-1836
72. Emsley J, McEwan P A., Gailani D. Structure and function of factor XI. Blood 2010 115 (13) 2569-2577
73. Ghosh K, Mota L, Shetty S, Kulkarni B. Spectrum of changes in endogenous thrombin potential due to heritable disorders of coagulation. Blood Coagul Fibrinolysis 2008 19 (6) 577-580
74. Mitka M. Guidelines for von Willebrand disease urge routine screening for bleeding. JAMA 2008 299 (16) 1890
75. Terraube V, O'Donnell J S., Jenkins P V. Factor VIII and von Willebrand factor interaction: biological, clinical and therapeutic importance. Haemophilia 2010 16 (1) 3-13
76. Mannucci P M. Treatment of von Willebrand's disease. N Engl J Med 2004 351 (7) 683-694
77. Béguin S, Kumar R, Keularts I, Seligsohn U, Coller B S., Hemker H C. Fibrin-dependent platelet procoagulant activity requires GPIb receptors and von Willebrand factor. Blood 1999 93 (2) 564-570
78. Rugeri L, Beguin S, Hemker C et al. Thrombin-generating capacity in patients with von Willebrand's disease. Haematologica 2007 92 (12) 1639-1646
79. Lippi G, Franchini M, Salvagno G L., Montagnana M, Poli G, Guidi G C. Correlation between von Willebrand factor antigen, von Willebrand factor ristocetin cofactor activity and factor VIII activity in plasma. J Thromb Thrombolysis 2008 26 (2) 150-153
80. Quiroga T, Goycoolea M, Giesen P L. et al. Thrombin generation in platelet-poor plasma is normal in patients with hereditary mucocutaneous haemorrhages. Pathophysiol Haemost Thromb 2003 33 (1) 30-35
81. Keularts I M., Hamulyak K, Hemker H C., Béguin S. The effect of DDAVP infusion on thrombin generation in platelet-rich plasma of von Willebrand type 1 and in mild haemophilia A patients. Thromb Haemost 2000 84 (4) 638-642
82. Al Dieri R, Peyvandi F, Santagostino E et al. The thrombogram in rare inherited coagulation disorders: its relation to clinical bleeding. Thromb Haemost 2002 88 (4) 576-582
83. van Veen J J., Gatt A, Makris M. Thrombin generation testing in routine clinical practice: are we there yet? Br J Haematol 2008 142 (6) 889-903
84. Spaanderman M E., Van Beek E, Ekhart T H. et al. Changes in hemodynamic parameters and volume homeostasis with the menstrual cycle among women with a history of preeclampsia. Am J Obstet Gynecol 2000 182 (5) 1127-1134
85. Shima M, Matsumoto T, Ogiwara K. New assays for monitoring haemophilia treatment. Haemophilia 2008 14 (Suppl 3) 83-92
86. Dargaud Y, Luddington R, Gray E et al. Effect of standardization and normalization on imprecision of calibrated automated thrombography: an international multicentre study. Br J Haematol 2007 139 (2) 303-309